Clinical Trial

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 21, 2024 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of patients with advanced esophageal squamous cell carcinoma treated with camrelizumab combined with Apatinib mesylate plus short-course chemotherapy versus standard chemotherapy in first line
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-12; most recent amendment 2024-11-20.
Trial Details
NCT Number NCT05738434
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions Esophageal Cancer by AJCC V8 Stage
Enrollment 188 participants
Start Date 2023-03-02
Primary Completion 2025-09-01 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-21